GlassScriptPhysician profile
Jason Cummings
NPI 1407426653
$1,937.36
in general payments reported to CMS, 2019-2025
20 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,050 · 2024: $628 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.99 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.06 | 2023-2025 | |
| Astellas Pharma US INC | $291.39 | 2023-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $205.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $132.15 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $124.99 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $97.61 | 2023-2024 | Breztri, Farxiga |
| Xeris Pharmaceuticals, INC. | $40.03 | 2023 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $29.94 | 2023 | |
| Glaxosmithkline, LLC. | $28.08 | 2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $26.92 | 2023 | Trintellix |
| Lilly USA, LLC | $23.36 | 2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $22.70 | 2023 | Rexulti |
| Nevro Corp. | $21.29 | 2023 | Senza |
| Philips North America LLC | $20.52 | 2025 | Extended Holter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.24 | 2023 | Xarelto |
| Hikma Pharmaceuticals USA | $17.86 | 2023 | Kloxxado, Ryaltris, Mitigare |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.31 | 2023 | Synjardy, Jardiance |
| Exact Sciences Corporation | $14.79 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $14.09 | 2023 | Verquvo, Belsomra, Lagevrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Cummings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.